Feasibility study of Bismuth Subsalicylate (BSS) as an addition to standard of care for COVID-19 therapy()

Detalles Bibliográficos
Autores principales: Yacyshyn, Mary Beth, Collins, James, Chua, Michelle, Siegwald, Angela, Yacyshyn, Sara, Briones-Pryor, Valerie, Yacyshyn, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964506/
https://www.ncbi.nlm.nih.gov/pubmed/35370296
http://dx.doi.org/10.1016/j.curtheres.2022.100667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964506/
https://www.ncbi.nlm.nih.gov/pubmed/35370296
http://dx.doi.org/10.1016/j.curtheres.2022.100667

Ejemplares similares